United Therapeuticsvs.Vertex Pharmaceuticals
UTHR vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 5.5× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.8 vs 29.1).
Side by side
| UTHR | VRTX | |
|---|---|---|
| Market cap | $23.4B | $128B |
| Price | $532.78 | $503.25 |
| Today | −2.2% | −0.5% |
| Return YTD | +11.9% | +11.5% |
| Return 1Y | +19.3% | +23.2% |
| Since June 26, 2026 | −1.8% | +2.4% |
| P/E | 17.8 | 29.1 |
| P/S | 7.4 | 10.2 |
| P/B | 3.7 | 6.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More UTHR & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.